

Massimo Di Maio

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1871763/massimo-di-maio-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

347
papers

8,742
citations

49
h-index

82
g-index

373
ext. papers

10,415
ext. citations

5.3
avg, IF

5.93
L-index

#	Paper	IF	Citations
347	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. <i>JAMA Network Open</i> , 2022 , 5, e220290	10.4	0
346	Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis.. <i>Tumori</i> , 2022 , 3008916221077144	1.7	0
345	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102583	2.2	4
344	A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 172, 103639	7	1
343	Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103649	7	1
342	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. <i>Cancer Treatment Reviews</i> , 2022 , 105, 102373	14.4	0
341	New emerging targets in advanced urothelial carcinoma: is it the primetime for personalized medicine?. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103682	7	2
340	Impact of Novel Hormonal Therapy on Cognitive Function: Essential to Measure, Difficult to Present.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200092	2.2	2
339	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide. <i>Minerva Urology and Nephrology</i> , 2021 ,	2.3	1
338	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-7	3.5	2
337	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021 , 11, e049128	3	1
336	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.. <i>Cancer Treatment Reviews</i> , 2021 , 103, 102326	14.4	0
335	Clinical Trials and Methodology of Cancer Research. <i>UNIPA Springer Series</i> , 2021 , 259-267	0.1	
334	A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021 , 2, 448-464	2.5	1
333	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	4
332	The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	12
331	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 2021 , 9,		20

330	Second medical opinion in oncological setting. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103282		1
329	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2) 2021 , 9,		3
328	Adoption of patient-reported outcomes (PROs) in clinical practice for older patients receiving active anticancer treatment: Impact on health-related quality of life (QoL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e24014-e24014	2.2	
327	Cancer patients' awareness about clinical research in the era of social media and fake news: Preliminary results from ELPIS Study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e24121-e24121	2.2	
326	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101681	2.4	
325	Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. <i>Cancers</i> , 2021 , 13,	6.6	1
324	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , 2021 , 21, 549	4.8	0
323	LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16102-e16102	2.2	0
322	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 0\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021 , 148, 24-35	7.5	8
321	Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. <i>European Journal of Cancer</i> , 2021 , 149, 49-60	7.5	
320	Tremellimumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021 , 13,	6.6	7
319	First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2917-2936	4.4	5
318	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2890-2916	4.4	6
317	Heterogeneity of treatment effects in malignant pleural mesothelioma. <i>Lancet, The</i> , 2021 , 398, 301-302	4.0	1
316	Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves. <i>JCO Oncology Practice</i> , 2021 , 17, e1887-e1894	2.3	1
315	Luteinized thecoma (thecomatosis) with sclerosing peritonitis: a systematic review of the literature of the last 25 years. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 23-32	3.5	2
314	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103185	7	15
313	A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system. <i>Supportive Care in Cancer</i> , 2021 , 29, 3219-3233	3.9	3

312	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	4
311	Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 320-320	2.2	0
310	A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 401-401	2.2	1
309	Hurrying up but not rushing, acting and not reacting, good sense and not common sense: Open thoughts and reasonable doubts on COVID-19 vaccination strategies in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 167, 103271	7	1
308	Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 812-825	6.2	1
307	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021 , 146, 145-154	7.5	6
306	Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. <i>Endocrine-Related Cancer</i> , 2021 , 28, R207-R216	5.7	4
305	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
304	Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries. <i>European Urology Oncology</i> , 2021 , 4, 1011-1011	6.7	1
303	Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	1
302	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019675	5.4	1
301	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
300	Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study. <i>ESMO Open</i> , 2020 , 5, e000876	6	4
299	Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020 , 10, 648	5.3	22
298	Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. <i>ESMO Open</i> , 2020 , 5,	6	14
297	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13315	4.6	21
296	Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. <i>Cancer Management and Research</i> , 2020 , 12, 3721-3729	3.6	11
295	Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). <i>Breast</i> , 2020 , 53, 18-22	3.6	5

294	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. <i>Clinical Lung Cancer</i> , 2020 , 21, e337-e348	4.9	4
293	Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. <i>Oncologist</i> , 2020 , 25, e946-e954	5.7	2
292	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. <i>Immunotherapy</i> , 2020 , 12, 151-159	3.8	8
291	Quality of life in patients with lung cancer: the way forward. <i>Lancet Oncology, The</i> , 2020 , 21, 617-619	21.7	2
290	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 661-668	5.7	6
289	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020 , 130, 155-167	7.5	53
288	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , 2020 , 16, e1304-e1314	2.3	26
287	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020 , 135, 230-239	7.5	6
286	Real-World Evidence in Oncology: Opportunities and Limitations. <i>Oncologist</i> , 2020 , 25, e746-e752	5.7	21
285	Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). <i>Clinical Colorectal Cancer</i> , 2020 , 19, 109-115	3.8	5
284	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102877	7	9
283	The Shifting Landscape of Genitourinary Oncology During the COVID-19 Pandemic and how Italian Oncologists Reacted: Results from a National Survey. <i>European Urology</i> , 2020 , 78, e27-e35	10.2	14
282	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1017-1024	12.9	8
281	FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4015-4015	2.2	7
280	Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): Individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4074-4074	2.2	3
279	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020 , 72, 737-745	4.4	4
278	Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: Retrospective analysis of clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6053-6053	2.2	
277	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15095-e15095	2.2	0

276	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102994	7	7
275	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Lung Cancer</i> , 2020 , 139, 47-54	5.9	18
274	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020 , 40, 704-711	7.9	25
273	Neuroendocrine breast carcinoma: a rare but challenging entity. <i>Medical Oncology</i> , 2020 , 37, 70	3.7	11
272	Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. <i>Cancers</i> , 2020 , 12,	6.6	3
271	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020 , 150, 123-131	5.9	4
270	Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020 , 12,	6.6	21
269	Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2020 , 12,	6.6	2
268	Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line Pazopanib in Metastatic reNal CELL Carcinoma (PIPELINE Study). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 621-627	2.7	0
267	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020 , JCO2001225	2.2	52
266	Carcinoid heart failure in a duodenal neuroendocrine tumor: role of cardiac surgery in a challenging patient and brief review of the literature. <i>Acta Oncologica</i> , 2020 , 59, 315-319	3.2	
265	Impact of primary tumor location on patterns of recurrence and survival of patients undergoing resection of liver metastases from colon cancer. <i>Hpb</i> , 2020 , 22, 116-123	3.8	8
264	The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings. <i>JAMA Oncology</i> , 2020 , 6, 926-927	13.4	2
263	Impact of adoption of patient-reported outcomes in clinical practice on the accuracy of symptom reporting in medical records of cancer patients. <i>Recenti Progressi in Medicina</i> , 2020 , 111, 740-748	0.7	
262	CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019 , 121, 593-599	8.7	14
261	Prophylactic cranial irradiation in extensive disease small cell lung cancer: An endless debate. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 143, 95-101	7	4
260	Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	12
259	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1458-1471	8.9	29

258	State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 87-90	7	15
257	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. <i>Frontiers in Oncology</i> , 2019 , 9, 264	5.3	59
256	Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 41-52	7	6
255	Reply to the letter to the editor 'On the underreporting of health-related quality of life and regulatory approval' by Bhamidipati et al. <i>Annals of Oncology</i> , 2019 , 30, 658-659	10.3	
254	The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients' quality of life. <i>Supportive Care in Cancer</i> , 2019 , 27, 4697-4704	3.9	7
253	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 332-347.e2	3.3	6
252	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130	7.5	29
251	Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach. <i>Journal of Oncology Practice</i> , 2019 , 15, 460-461	3.1	2
250	Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. <i>In Vivo</i> , 2019 , 33, 2021-2026	2.3	1
249	Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol. <i>BMJ Open</i> , 2019 , 9, e031485	3	6
248	Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12507-e12507	2.2	2
247	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 219-219	2.2	3
246	Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases. <i>Endokrynologia Polska</i> , 2019 , 70, 380-383	1.1	2
245	Second-line treatment options in hepatocellular carcinoma. <i>Drugs in Context</i> , 2019 , 8, 212577	5.2	21
244	Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer 2019 , 497-511		
243	Host metabolic factors and prognosis in patients treated with immune checkpoint inhibitors for advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14162-e14162	2.2	
242	Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14077-e14077	2.2	
241	Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20565-e20565	2.2	

240	Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 91-91	2.2	0
239	Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. <i>Future Oncology</i> , 2019 , 15, 2543-2553	3.6	6
238	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019 , 74, 35-42	14.4	20
237	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019 , 38, 835-844	4	17
236	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e735-e742	3.3	10
235	Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 124, 21-28	7	11
234	A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 122, 21-29	7	10
233	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018 , 155, 479-489.e7	13.3	36
232	Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?. <i>Future Oncology</i> , 2018 , 14, 1223-1231	3.6	3
231	Loss of C/EBP- β drives cisplatin resistance in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2018 , 120, 34-45	5.9	16
230	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018 , 19, 93-104	4.9	31
229	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 191-198	4.9	1
228	MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. <i>International Journal of Clinical Oncology</i> , 2018 , 23, 281-286	4.2	1
227	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018 , 25, R1-R9	5.7	10
226	Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 129, 54-66	7	19
225	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. <i>Cancer Treatment Reviews</i> , 2018 , 69, 215-223	14.4	11
224	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 129, 124-132	7	11
223	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. <i>Clinical and Translational Radiation Oncology</i> , 2018 , 12, 47-52	4.6	8

222	Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1087-e1090	3.3	2
221	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 318-324	3.3	2
220	Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM protocol 2802).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3542-3542	2.2	3
219	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the BRAF, BeCool platform.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 639-639	2.2	2
218	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. <i>Oncotarget</i> , 2018 , 9, 6630-6643	5.43	26
217	Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18719-e18719	2.2	
216	Moving from the CLEOPATRA study to real life: Results from the G.O.N.O. SUPER trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13006-e13006	2.2	
215	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2018 , 3, e000389	6	3
214	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. <i>OncoTargets and Therapy</i> , 2018 , 11, 7353-7368	4.4	41
213	Frequent fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. <i>Oncotarget</i> , 2018 , 9, 9661-9671	3.3	23
212	A review of guidelines for lung cancer. <i>Journal of Thoracic Disease</i> , 2018 , 10, S1556-S1563	2.6	41
211	Hormonal treatment and quality of life of prostate cancer patients: new evidence. <i>Minerva Urology and Nephrology</i> , 2018 , 70, 144-151	2.3	18
210	Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. <i>Annals of Oncology</i> , 2018 , 29, 2288-2295	10.3	35
209	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , 2018 , 10, 1229-1239	3.8	22
208	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018 , 42, 41-49	3.6	49
207	Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?. <i>JAMA Oncology</i> , 2017 , 3, 1170-1171	13.4	6
206	Patients' perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey. <i>European Journal of Cancer Care</i> , 2017 , 26, e12618	2.4	58
205	Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey. <i>Clinical Lung Cancer</i> , 2017 , 18, 381-387	4.9	5

204	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. <i>Acta Oncologica</i> , 2017 , 56, 555-562	3.2	20
203	Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2017 , 11, 171-180	3.8	7
202	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. <i>Cancer Treatment Reviews</i> , 2017 , 54, 1-9	14.4	26
201	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial. <i>Lung Cancer</i> , 2017 , 108, 15-21	5.9	7
200	Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1264	2.2	1
199	Zoledronic Acid Dosing Interval for Metastatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1477-1478	27.4	
198	Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. <i>Lung Cancer</i> , 2017 , 111, 30-37	5.9	20
197	Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors. <i>Radiology and Oncology</i> , 2017 , 51, 241-251	3.8	1
196	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017 , 2017, 5618174	3	8
195	Outcomes research: Integrating PROs into the clinic - overall survival benefit or not, it's worth the trouble. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 529-530	19.4	10
194	Quality of life: an important element of treatment value. <i>Lancet Oncology, The</i> , 2017 , 18, 1557-1558	21.7	4
193	Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2017 , 18, 23-33.e1	4.9	11
192	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11508-11508	2.2	1
191	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017 , 8, 57528-57536	3.3	7
190	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017 , 49, 834-845	5.2	9
189	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017 , 8, 112816-112824	3.3	1
188	Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer 2017 , 1-15		1
187	Trends in exposure to multiple lines of treatment and survival of patients with metastatic renal cell carcinoma: A real-world analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16064-e16064	2.2	0

186	Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 1053-62	3.5	14
185	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016 , 100, 30-37	5.9	3
184	Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy. <i>Radiologia Medica</i> , 2016 , 121, 950-957	6.5	3
183	Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 504-15	8.9	14
182	Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 319-25	19.4	125
181	Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 653-60	3.5	83
180	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016 , 44, 61-73	14.4	50
179	BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. <i>Lung Cancer</i> , 2016 , 95, 73-81	5.9	14
178	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016 , 69, 563-573	10.2	82
177	The ICET-A Survey on Current Criteria Used by Clinicians for the Assessment of Central Adrenal Insufficiency in Thalassemia: Analysis of Results and Recommendations. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016034	3.2	7
176	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016 , 11, e0159146	3.7	2
175	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016 , 7, 72654-72661	3.3	7
174	Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016 , 5, 89-91	4.4	1
173	Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions. <i>Anticancer Research</i> , 2016 , 36, 5163-5170	2.3	0
172	PRO-BMI study: prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16543-e16543	2.2	2
171	Predictive role of clinical benefit (CB) at 1st line on the outcome of subsequent lines in metastatic breast cancer (MBC) patients: analysis of a real life population.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e12027-e12027	2.2	0
170	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <i>Translational Lung Cancer Research</i> , 2016 , 5, 301-21	4.4	33
169	Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy. <i>Analytical Cellular Pathology</i> , 2016 , 2016, 4918325	3.4	7

168	Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. <i>Sarcoma</i> , 2016 , 2016, 6862090	3.1	7
167	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. <i>Lancet Oncology</i> , 2016 , 17, 1137-1146	21.7	82
166	Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2016 , 1, e000109	6	1
165	Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology: Beyond Citation Counts. <i>JAMA Oncology</i> , 2016 , 2, 1510-1511	13.4	1
164	The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 104, 9-20	7	57
163	LUX-Lung 7: is there enough data for a final conclusion?. <i>Lancet Oncology</i> , 2016 , 17, e266	21.7	
162	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. <i>Clinical Lung Cancer</i> , 2015 , 16, 262-73	4.9	36
161	Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015 , 88, 319-24	5.9	4
160	Papillary renal cell carcinoma: A review of the current therapeutic landscape. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 100-12	7	72
159	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 561-8	21.7	109
158	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2015 , 16, 325-33	4.9	55
157	Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. <i>Annals of Oncology</i> , 2015 , 26, 675-682	10.3	37
156	Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. <i>Lung Cancer</i> , 2015 , 90, 234-42	5.9	10
155	BRAF-mutated metastatic colorectal cancer between past and future. <i>British Journal of Cancer</i> , 2015 , 113, 1634-5	8.7	10
154	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2015 , 41, 884-92	14.4	105
153	Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature. <i>BMC Cancer</i> , 2015 , 15, 914	4.8	5
152	Reply to P. Baldo et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2826	2.2	
151	Subgroup Analysis: Refining a Positive Result or Trying to Rescue a Negative One?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4310	2.2	2

150	LUX-Lung: determining the best EGFR inhibitor in NSCLC?. <i>Lancet Oncology, The</i> , 2015 , 16, 118-9	21.7	9
149	Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 910-5	2.2	262
148	A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomy. <i>European Journal of Cardio-thoracic Surgery</i> , 2015 , 48, 196-200	3	44
147	Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0133488	3.7	76
146	The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer. <i>Translational Lung Cancer Research</i> , 2015 , 4, 15-7	4.4	1
145	Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16066-e16066	2.2	
144	Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2014 , 15, 166-70	4.9	24
143	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 396-405	21.7	271
142	Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014 , 15, 1254-62	21.7	71
141	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014 , 15, 173-81	4.9	50
140	Treatment of small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 91, 257-70	7	49
139	Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' reply. <i>Lancet Oncology, The</i> , 2014 , 15, e250-1	21.7	2
138	Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review). <i>International Journal of Oncology</i> , 2014 , 45, 509-15	4.4	10
137	Clinical and organizational issues in the management of surviving breast and colorectal cancer patients: attitudes and feelings of medical oncologists. <i>PLoS ONE</i> , 2014 , 9, e101170	3.7	6
136	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). <i>BMC Cancer</i> , 2014 , 14, 875	4.8	27
135	New biological treatments for gynecological tumors: focus on angiogenesis. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 337-46	5.4	6
134	Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. <i>Liver International</i> , 2014 , 34, 1109-17	7.9	15
133	management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. <i>Clinical Lung Cancer</i> , 2014 , 15, 307-12	4.9	22

132	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 135-45	7	11
131	Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 314-9	5.9	50
130	Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3901-13	3.3	6
129	Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. <i>Cancer Treatment Reviews</i> , 2013 , 39, 498-506	14.4	34
128	Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). <i>Lung Cancer</i> , 2013 , 82, 115-20	5.9	8
127	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1207-18	3.5	10
126	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. <i>Lung Cancer</i> , 2013 , 81, 77-83	5.9	36
125	Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2013 , 79, 20-6	5.9	37
124	Afatinib in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2013 , 2, 493-504	2.6	
123	Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. <i>Future Oncology</i> , 2013 , 9, 1841-8	3.6	3
122	The role of meta-analysis in defining clinical practice in advanced non-small-cell lung cancer. <i>Clinical Investigation</i> , 2013 , 3, 523-530		
121	Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. <i>Anti-Cancer Drugs</i> , 2013 , 24, 99-111	2.4	13
120	Integrated therapeutic approaches in the treatment of locally advanced non-small cell lung cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013 , 13, 844-51	2.2	2
119	Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , 2013 , 99, 35-8	1.7	
118	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1830-1844	8.9	17
117	Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2012 , 1, 55-62	2.6	1
116	Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 233-42	8.9	4
115	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3002-11	2.2	193

114	Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. <i>Lung Cancer</i> , 2012 , 76, 269-79	5.9	20
113	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , 2012 , 76, 457-64	5.9	14
112	Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. <i>Lung Cancer</i> , 2012 , 77, 116-20	5.9	9
111	Cetuximab in non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 163-75	3.5	16
110	Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. <i>Scientific World Journal, The</i> , 2012 , 2012, 564706	2.2	19
109	Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. <i>Cancers</i> , 2012 , 4, 549-65	6.6	1
108	Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. <i>Annals of Oncology</i> , 2012 , 23, 2027-2033	10.3	18
107	Corrigendum to 'Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery?' [Eur J Cardiothorac Surg 2011;40:912-18]. <i>European Journal of Cardio-thoracic Surgery</i> , 2012 , 41, 1411-1411	3	
106	Bevacizumab in non small cell lung cancer: development, current status and issues. <i>Current Medicinal Chemistry</i> , 2012 , 19, 961-71	4.3	17
105	Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1692-8	2.2	292
104	Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. <i>Oncology Reports</i> , 2012 , 27, 1849-56	3.5	40
103	A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4151-TPS4151	2.2	2
102	Conventional chemotherapy of advanced pancreatic cancer. <i>Current Drug Targets</i> , 2012 , 13, 795-801	3	10
101	Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 299-307	3.5	5
100	Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). <i>Lung Cancer</i> , 2011 , 73, 78-88	5.9	4
99	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. <i>Lung Cancer</i> , 2011 , 71, 249-57	5.9	92
98	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. <i>Lung Cancer</i> , 2011 , 72, 3-8	5.9	35
97	Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. <i>Lung Cancer</i> , 2011 , 73, 1-10	5.9	21

96	Maintenance therapy in NSCLC: why? To whom? Which agent?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 50	12.8	19
95	Disparity in the time to patient access to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , 2011 , 97, 442-448	1.7	4
94	A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 427-32	8.7	38
93	Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. <i>BMC Cancer</i> , 2011 , 11, 75	4.8	12
92	Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. <i>Annals of Oncology</i> , 2011 , 22, 1528-1534	10.3	42
91	Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3628-35	2.2	149
90	Gefitinib in non small cell lung cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 815269		14
89	Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. <i>Annals of Oncology</i> , 2011 , 22, 376-82	10.3	13
88	Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective study. <i>Oncology</i> , 2011 , 81, 104-12	3.6	21
87	Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery?. <i>European Journal of Cardio-thoracic Surgery</i> , 2011 , 40, 912-6	3	38
86	Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , 2011 , 97, 442-8	1.7	2
85	Time spent for activation of non-profit studies in oncology in Italy. <i>PLoS ONE</i> , 2010 , 5, e11864	3.7	3
84	Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1645-51	2.2	237
83	Vinorelbine for non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 493-510	4.1	10
82	Endoscopic surveillance for hereditary non-polyposis colorectal cancer (HNPCC) family members in a Southern Italian region. <i>Digestive and Liver Disease</i> , 2010 , 42, 698-703	3.3	
81	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010 , 67, 86-92	5.9	19
80	Methodological aspects of lung cancer clinical trials in the era of targeted agents. <i>Lung Cancer</i> , 2010 , 67, 127-35	5.9	26
79	Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Lung Cancer</i> , 2010 , 68, 319-31	5.9	50

78	Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. <i>Lung Cancer</i> , 2010 , 70, 119-28	5.9	48
77	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. <i>European Journal of Cancer</i> , 2010 , 46, 735-43	7.5	60
76	The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 321-4	4	5
75	New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1503-14	5.9	8
74	Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. <i>Leukemia Research</i> , 2010 , 34, 1576-88	2.7	100
73	Vandetanib: An overview of its clinical development in NSCLC and other tumors. <i>Drugs of Today</i> , 2010 , 46, 683-98	2.5	24
72	Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). <i>Tumori</i> , 2010 , 96, 1010-5	1.7	9
71	Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1836-43	2.2	137
70	Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. <i>Oncologist</i> , 2009 , 14, 378-90	5.7	152
69	Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBEO trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3192-7	2.2	68
68	Cetuximab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2009 , 361, 95; author reply 96-7	59.2	9
67	Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?. <i>Journal of Clinical Oncology</i> , 2009 , 27, e123; author reply e124-5	2.2	2
66	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 1021-7	3.5	8
65	Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. <i>Lung Cancer</i> , 2009 , 63, 251-8	5.9	26
64	Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2009 , 66, 8-14	5.9	25
63	Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 505-6	19.4	30
62	Targeting targeted agents: open issues for clinical trial design. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 66	12.8	15
61	Palonosetron: more than just another option?. <i>Lancet Oncology</i> , 2009 , 10, 100-1	21.7	2

60	Registrative trials of antiemetic drugs: arrival or starting point?. <i>Lancet Oncology, The</i> , 2009 , 10, 533-4	21.7	1
59	Re: Design and endpoints of clinical trials in hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1557; author reply 1557-8	9.7	12
58	Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter?. <i>Annals of Oncology</i> , 2008 , 19, 402-3	10.3	5
57	153Sm: its use in multiple myeloma and report of a clinical experience. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1379-87	5.9	14
56	Second-line treatment of advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 430-40	8.9	52
55	Is human hepatocellular carcinoma a hormone-responsive tumor?. <i>World Journal of Gastroenterology</i> , 2008 , 14, 1682-9	5.6	37
54	A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. <i>Clinical Lung Cancer</i> , 2007 , 8, 568-71	4.9	18
53	Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. <i>Hepatology Research</i> , 2007 , 37 Suppl 2, S206-9	5.1	18
52	The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. <i>Supportive Care in Cancer</i> , 2007 , 15, 179-85	3.9	100
51	Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 63, 53-64	7	20
50	A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. <i>British Journal of Cancer</i> , 2007 , 96, 1639-43	8.7	23
49	Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 605-6; author reply 606-7	2.2	3
48	Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1377-82	2.2	98
47	Triplet repeat instability correlates with dinucleotide instability in primary breast cancer. <i>Oncology Reports</i> , 2007 , 17, 193	3.5	1
46	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology, The</i> , 2007 , 8, 500-12	21.7	80
45	Incidence and pathological characteristics of prostate cancer in Italy: a contribution to the screening debate. <i>Cancer Detection and Prevention</i> , 2006 , 30, 455-8		3
44	Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2006 , 6, 196	4.8	16
43	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. <i>BMC Cancer</i> , 2006 , 6, 202	4.8	18

42	Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. <i>BMC Cancer</i> , 2006 , 6, 5	4.8	88
41	Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 114-5		9
40	Factorial design for randomized clinical trials. <i>Annals of Oncology</i> , 2006 , 17, 1607-8	10.3	4
39	Medical treatment of resistant or recurrent epithelial ovarian cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 7, vii49-50	10.3	4
38	Methodology of clinical trials with new molecular-targeted agents: where do we stand?. <i>Annals of Oncology</i> , 2006 , 17 Suppl 7, vii128-31	10.3	21
37	Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. <i>British Journal of Cancer</i> , 2006 , 94, 1233-6	8.7	26
36	Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. <i>Oncologist</i> , 2006 , 11, 753-64	5.7	221
35	Significance of erb-B2 immunoreactivity in cervical cancer. <i>Frontiers in Bioscience - Landmark</i> , 2006 , 11, 2071-6	2.8	3
34	The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. <i>Frontiers in Bioscience - Landmark</i> , 2006 , 11, 1585-90	2.8	10
33	Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 59, 243-9	7	40
32	Hormonal treatment of human hepatocellular carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1089, 252-61	6.5	25
31	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. <i>Lancet Oncology</i> , 2005 , 6, 669-77	21.7	177
30	Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. <i>Endocrine-Related Cancer</i> , 2005 , 12, 721-47	5.7	214
29	Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. <i>Current Opinion in Oncology</i> , 2005 , 17, 123-9	4.2	7
28	Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. <i>BMC Cancer</i> , 2005 , 5, 30	4.8	26
27	Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Journal of Cellular Physiology</i> , 2005 , 205, 355-63	7	26
26	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 44-50	7.4	12
25	Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6815-22	2.2	394

24	Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3125-37	2.2	152
23	Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). <i>Journal of Clinical Oncology</i> , 2004 , 22, 5018-20; author reply 5020-1	2.2	20
22	Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2035-6; author reply 2036-7	2.2	9
21	Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. <i>Annals of Oncology</i> , 2004 , 15, 419-26	10.3	121
20	Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2004 , 90, 2288-96	8.7	96
19	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. <i>British Journal of Cancer</i> , 2004 , 91, 1996-2004	8.7	151
18	Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. <i>Supportive Care in Cancer</i> , 2004 , 12, 446-53	3.9	29
17	Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer. <i>Archives of Dermatological Research</i> , 2004 , 296, 141-2	3.3	6
16	The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 52, 33-44	7	26
15	An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. <i>Annals of Oncology</i> , 2003 , 14, 1406-11	10.3	10
14	Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study. <i>Oncology</i> , 2003 , 64, 479-80	3.6	12
13	Supportive care in patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2003 , 89, 1013-21	8.7	22
12	Quality of Life in elderly patients with cancer. <i>Health and Quality of Life Outcomes</i> , 2003 , 1, 44	3	56
11	Statistical design in phase II clinical trials and its application in breast cancer. <i>Lancet Oncology</i> , 2003 , 4, 305-11	21.7	22
10	Single Agents or Combination Chemotherapy for Advanced Ovarian Carcinoma in Elderly Patients: Pro Single Agents. <i>Tumori</i> , 2002 , 88, S117-S119	1.7	
9	Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 52-7	2.2	8
8	p53 expression is decreased in primary breast carcinomas with microsatellite instability. <i>Breast Cancer Research and Treatment</i> , 2002 , 73, 257-66	4.4	5
7	Survey of Modalities of Toxicity Assessment and Reporting in Noncomparative Prospective Studies of Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 52-57	2.2	4

6	Hepatocellular carcinoma: systemic treatments. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, S109-14	3	50
5	Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. <i>Current Pharmaceutical Design</i> , 2002 , 8, 1013-9	3-3	37
4	Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. <i>Lung Cancer</i> , 2002 , 36, 327-32	5-9	17
3	Pancreatic Involvement from Heavily Pretreated Small Cell Lung Cancer Successfully Treated with Transcatheter Intra-Arterial Chemotherapy: A Case Report with Local and Systemic Disease Control. <i>Tumori</i> , 2002 , 88, 535-537	1-7	1
2	Indication for Venous Ports in Oncology Comparing Different Experiences in Europe. <i>Tumori</i> , 2001 , 87, 69-70	1-7	3
1	Advanced hepatocellular carcinoma: Impact of systemic treatments on health-related quality of life and patient-reported outcomes. <i>Liver Cancer International</i> ,	0-8	0